Olema Pharmaceuticals Inc... (OLMA)
4.21
-0.16 (-3.66%)
At close: Mar 03, 2025, 3:53 PM
No 1D chart data available
| Bid | 4.21 |
| Market Cap | 288.02M |
| Revenue (ttm) | 2.25M |
| Net Income (ttm) | -146.4M |
| EPS (ttm) | -2.28 |
| PE Ratio (ttm) | -1.85 |
| Forward PE | -2.28 |
| Analyst | Buy |
| Ask | 4.22 |
| Volume | 1,001,155 |
| Avg. Volume (20D) | 1,156,468 |
| Open | 4.36 |
| Previous Close | 4.37 |
| Day's Range | 4.18 - 4.58 |
| 52-Week Range | 4.18 - 16.62 |
| Beta | 2.06 |
About OLMA
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negativ...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 19, 2020
Employees 87
Stock Exchange NASDAQ
Ticker Symbol OLMA
Website https://www.olema.com
Analyst Forecast
According to 4 analyst ratings, the average rating for OLMA stock is "Buy." The 12-month stock price forecast is $30, which is an increase of 611.74% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
3 months ago
+0.89%
Olema Pharmaceutical shares are trading higher aft...
Unlock content with
Pro Subscription
